A Phase 3, Randomized study of atezolizumab plus bevacizumab and chemotherapy in patients with EGFR or ALK mutated in non-small cell lung cancer (ATTLAS, KCSG-LU19-04).

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)

mutated NSCLC who have progressed on relevant targeted therapy.

Keyphrases